Technology
CAR-T cell therapy
Autologous CAR-T cell therapy
Hybrid CAR
Chimeric Antigen Receptor (CAR) T cells use antibodies to recognize antigen proteins on the cancer and oftenly normal cell surface. Inside T cell there is a molecule called intracellular signaling domain, enhancing its activity.
Approved CAR-T cells` breakthrough efficacy against hematological B cell tumors is accompanied with high on-target/ off-tumor toxicity because target antigens are expressed on both cancer and normal B cells. Basically, current CAR-T cells indiscriminately attack cancer and normal B cells marked by targeted antigen.
TCR-T cell receptors recognize cancer-specific antigen derived peptides expressed in complex with HLA on cancer cell surface and attack them. Initially naive cancer-specific receptors were transferred to T cells with some modest results. Nowadays cancer-specific receptors with enhanced affinity are mostly used in TCR-T cells clinical studies. So TCR-T cell approach is more cancer-specific, but yet to demonstrate comparable results for solid tumors.
Our exceedingly powerful and precise Hybrid CAR-T cell therapy combines CAR-T cell power with TCR-T cell precision.
